Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-week randomized double-blind placebo-controlled trial of lurasidone in major depressive disorder with mixed features
2012-004132-33Phase 3Terminated
- Sponsor
- Sunovion
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lurasidone 20–60 mg/day with Placebo (2 arms). Primary endpoint: Change in MADRS total score from baseline to week 6. Started Jan 2013; status: terminated.
02
Drugs
lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2012-004132-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004132-33.